Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model

The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCro...

Full description

Saved in:
Bibliographic Details
Published inBMC immunology Vol. 22; no. 1; p. 68
Main Authors Kang, Kyu Ri, Huh, Dong Ho, Kim, Ji Ahn, Kang, Jin Han
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 12.10.2021
BioMed Central
BMC
Subjects
Adhesins, Bacterial - immunology
Adolescent
Adult
Analysis
Animal models
Animals
Antibodies
Antibody response
Antigens
Bordetella pertussis
Bordetella pertussis - physiology
Cell-mediated immunity
Cells, Cultured
Diphtheria
Diphtheria-Tetanus-Pertussis Vaccine - immunology
Disease Models, Animal
DPT vaccine
Helper cells
Hemagglutinins
Humans
Immune response (humoral)
Immunity, Humoral
Immunization, Secondary
Immunogenetics
Immunogenicity
Immunogenicity, Vaccine
Innovations
Interferon gamma
Interferon-gamma - metabolism
Interleukin 17
Interleukin 5
Korea
Laboratory animals
Lymphocytes T
Methods
Mice
Mice, Inbred BALB C
Mouse study
Pertussis
Statistical analysis
Teenagers
Testing
Tetanus
Tetanus-reduced dose diphtheria-acellular pertussis vaccine
Th1 Cells - immunology
Vaccines
Virulence Factors, Bordetella - immunology
Whooping cough
Whooping Cough - immunology
γ-Interferon
Korea
South Korea
United States > US
Immunogenicity
Mouse study
Tetanus-reduced dose diphtheria-acellular pertussis vaccine
Online AccessGet full text

Cover

Abstract The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-γ) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
AbstractList The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-γ) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-[gamma]) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
Abstract Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Methods Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-γ) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Results Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Conclusions Our results confirmed the immunogenicity of GC Pharma’s Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Methods Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-[gamma]) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Results Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Conclusions Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression. Keywords: Tetanus-reduced dose diphtheria-acellular pertussis vaccine, Immunogenicity, Mouse study
Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Methods Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-γ) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Results Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Conclusions Our results confirmed the immunogenicity of GC Pharma’s Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
Abstract Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. Methods Two tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-γ) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. Results Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. Conclusions Our results confirmed the immunogenicity of GC Pharma’s Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
BACKGROUNDThe necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the vaccine, GC3111, produced previously in 2010 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, immunogenicity and efficacy of the enhanced Tdap vaccine compared and evaluated with two Tdap vaccines, GC3111 vaccine produced in 2010 previously and commercially available Tdap vaccine in a murine model. METHODSTwo tests groups and positive control group of Balb/c mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 9 week using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The enhanced GC3111 generated similar humoral response compare to the commercial vaccine for filamentous hemagglutinin (FHA). The interferon gamma (IFN-γ) (Th1), interleukin 5 (IL-5) (Th2) and interleukin 17 (IL-17) (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens (hBp + antigen). A bacterial challenge test was performed 4 weeks after booster vaccination. RESULTSRegarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between two test groups and positive control group. All the vaccinated groups indicated a Th1 or Th1/Th2 response. On Day 5 post-bacterial challenge, B. pertussis colonies were absent in the lungs in two test groups and positive control group. CONCLUSIONSOur results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.
ArticleNumber 68
Audience Academic
Author Kim, Ji Ahn
Kang, Kyu Ri
Kang, Jin Han
Huh, Dong Ho
Author_xml – sequence: 1
  givenname: Kyu Ri
  surname: Kang
  fullname: Kang, Kyu Ri
  organization: The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Annex to Seoul Saint Mary Hospital, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea
– sequence: 2
  givenname: Dong Ho
  surname: Huh
  fullname: Huh, Dong Ho
  organization: The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Annex to Seoul Saint Mary Hospital, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea
– sequence: 3
  givenname: Ji Ahn
  surname: Kim
  fullname: Kim, Ji Ahn
  organization: The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Annex to Seoul Saint Mary Hospital, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea
– sequence: 4
  givenname: Jin Han
  orcidid: 0000-0003-1610-6742
  surname: Kang
  fullname: Kang, Jin Han
  email: kjhan@catholic.ac.kr, kjhan@catholic.ac.kr
  organization: Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea. kjhan@catholic.ac.kr
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34641798$$D View this record in MEDLINE/PubMed
BookMark eNptkstu1DAUhiNURC_wAixQJDbtIsW3JM4GqVRcRqqEBGVtndgnM64Se7CdQl-DJ8bTKWUGIS98-85_5N__cXHgvMOieEnJOaWyeRMpk01dEUYrQkTdVvRJcURFSytGW3awsz4sjmO8IYS2kslnxSEXjaBtJ4-KX4tpmp1forPaprvSDyWUDn-U6FbgNJoyYQI3xyqgmTd74yOWxq5XaYXBQgUax3EeIZRrDGmO0cby9NrA-qy8Ba2twxKWYF1M5TsfDKaMww5rXe44zWEDTt7g-Lx4OsAY8cXDfFJ8-_D--vJTdfX54-Ly4qrSddemqtYDMYZSY6RsBeV11xvC-oa1nEFrJKkJZJCyVgDhAwqCDM1QU-REYAP8pFhsdY2HG7UOdoJwpzxYdX_gw1JBSFaPqPjQgBC8r3WvBWu4JDi0bU9ZV6OhQ5e13m611nM_odHoUoBxT3T_xtmVWvpbJWvSiI5ngdMHgeC_zxiTmmzcOAsO_RwVqyWVjEkmMvr6H_TGz8FlqzLVES4pZ_Vfagn5AdYNPvfVG1F10UjaZBMYy9T5f6g8DE5W57gNNp_vFZztFWQm4c-0hPyZavH1yz7LtqwOPsaAw6MflKhNgtU2wSonWN0nWNFc9GrXyceSP5HlvwExBO2d
CitedBy_id crossref_primary_10_1007_s00253_022_11798_1
crossref_primary_10_3390_vaccines12010108
Cites_doi 10.1086/315318
10.1016/j.vaccine.2012.06.005
10.1128/IAI.66.8.3796-3801.1998
10.1016/S0264-410X(98)00226-6
10.1016/j.coi.2019.03.006
10.3346/jkms.2012.27.12.1547
10.7774/cevr.2019.8.1.35
10.1038/ni1449
10.1099/jmm.0.000829
10.1073/pnas.1314688110
10.1056/NEJMp1209051
10.1186/s12879-017-2369-x
10.1016/j.vaccine.2015.01.063
10.3201/eid1508.081511
10.1128/iai.65.12.4904-4908.1997
10.1016/j.jpeds.2012.05.041
10.3346/jkms.2014.29.5.652
10.1128/iai.61.2.399-410.1993
10.1371/journal.ppat.1003264
10.1093/infdis/jit560
10.1056/NEJMoa1200850
10.1016/j.vaccine.2006.01.021
10.1097/01.inf.0000160914.59160.41
10.1093/femspd/ftv067
10.1086/315509
10.1016/j.jmii.2017.04.003
10.1016/S0264-410X(02)00823-X
10.1128/CVI.00328-09
10.3201/eid2004.131478
10.1007/s00005-013-0242-1
10.3346/jkms.2015.30.7.988
10.1128/IAI.67.8.4064-4071.1999
10.1046/j.1365-2567.1998.00401.x
10.7774/cevr.2015.4.1.75
10.3389/fimmu.2014.00520
10.1093/cid/ciw634
10.3201/eid2512.181836
10.1186/1471-2334-13-151
10.1128/CDLI.6.4.464-470.1999
10.1016/S0264-410X(98)00227-8
10.1111/j.1469-0691.2012.03925.x
10.2807/1560-7917.ES2014.19.33.20881
10.1084/jem.186.11.1843
10.1016/S0264-410X(99)00038-9
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ISR
3V.
7T5
7X7
7XB
88E
8C1
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12865-021-00457-1
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE



Publicly Available Content Database
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1471-2172
EndPage 68
ExternalDocumentID oai_doaj_org_article_3f6a443b5cbc426380ef77b1295ed1f9
A681630422
10_1186_s12865_021_00457_1
34641798
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Korea
South Korea
United States--US
GeographicLocations_xml – name: Korea
– name: South Korea
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 5-2018-D0083-0001; 5-2019-D0083-00002; 5-2018-D0083-0001; 5-2019-D0083-00002; 5-2018-D0083-0001; 5-2019-D0083-00002; 5-2018-D0083-0001; 5-2019-D0083-00002
GroupedDBID ---
-A0
0R~
23N
2WC
3V.
53G
5VS
6J9
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFGXO
AFKRA
AFNRJ
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBS
ECM
EIF
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
M1P
M48
M7P
M~E
NPM
O5R
O5S
OK1
P2P
PIMPY
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
ACMJI
ALIPV
CITATION
EBLON
PGMZT
ABVAZ
LK8
7T5
7XB
8FE
8FH
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c597t-5cf0dd11dd88741359bd02b62732a7d8050a5971274a03fe40e2edf51e304e6a3
IEDL.DBID RPM
ISSN 1471-2172
IngestDate Thu Jul 04 21:10:42 EDT 2024
Tue Sep 17 21:16:54 EDT 2024
Sat Aug 17 02:47:42 EDT 2024
Fri Sep 13 06:37:28 EDT 2024
Thu Feb 22 23:36:19 EST 2024
Fri Feb 02 04:30:24 EST 2024
Thu Aug 01 20:39:15 EDT 2024
Thu Sep 12 16:27:11 EDT 2024
Thu May 23 23:36:53 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Immunogenicity
Mouse study
Tetanus-reduced dose diphtheria-acellular pertussis vaccine
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c597t-5cf0dd11dd88741359bd02b62732a7d8050a5971274a03fe40e2edf51e304e6a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-1610-6742
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506493/
PMID 34641798
PQID 2590381325
PQPubID 44823
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_3f6a443b5cbc426380ef77b1295ed1f9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8506493
proquest_miscellaneous_2581822824
proquest_journals_2590381325
gale_infotracmisc_A681630422
gale_infotracacademiconefile_A681630422
gale_incontextgauss_ISR_A681630422
crossref_primary_10_1186_s12865_021_00457_1
pubmed_primary_34641798
PublicationCentury 2000
PublicationDate 2021-10-12
PublicationDateYYYYMMDD 2021-10-12
PublicationDate_xml – month: 10
  year: 2021
  text: 2021-10-12
  day: 12
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC immunology
PublicationTitleAlternate BMC Immunol
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References HJ Kwon (457_CR12) 2012; 27
KH Mills (457_CR29) 1993; 61
JD Cherry (457_CR2) 2012; 367
H Campbell (457_CR27) 2018; 67
PJ Ross (457_CR38) 2013; 9
SY Lee (457_CR13) 2014; 29
A Bechini (457_CR25) 2012; 30
HJ Kwon (457_CR15) 2017; 17
J Brummelman (457_CR40) 2015; 33
K Winter (457_CR1) 2012; 161
DH Huh (457_CR17) 2018; 51
JB Bruss (457_CR19) 1999; 6
G Vidarsson (457_CR21) 2014; 5
JD Cherry (457_CR20) 1998; 16
SA Khader (457_CR34) 2007; 8
SB Han (457_CR16) 2015; 4
C Lam (457_CR8) 2014; 20
A Giammanco (457_CR23) 2003; 21
G Fedele (457_CR35) 2013; 61
M Ryan (457_CR44) 1998; 93
A Zeddeman (457_CR7) 2014; 19
J Barbic (457_CR32) 1997; 65
P Kapil (457_CR41) 2019; 59
NP Klein (457_CR5) 2012; 367
C Park (457_CR14) 2019; 8
C Boursaux-Eude (457_CR18) 1999; 17
CM Ausiello (457_CR42) 1999; 67
J Storsaeter (457_CR22) 1998; 16
F Vermeulen (457_CR37) 2010; 17
N Hegerle (457_CR6) 2012; 18
E Chiappini (457_CR3) 2013; 13
L Li (457_CR10) 2019; 25
J Taranger (457_CR24) 2000; 181
S Mazzilli (457_CR28) 2018; 30
A Wendelboe (457_CR4) 2005; 24
KM Edwards (457_CR45) 2014; 209
CM Ausiello (457_CR30) 2000; 181
JM Warfel (457_CR33) 2014; 111
Q He (457_CR43) 1998; 66
E Reynolds (457_CR39) 2006; 24
FR Mooi (457_CR9) 2009; 15
SY Lee (457_CR11) 2015; 30
BP Mahon (457_CR31) 1997; 186
J Brummelman (457_CR36) 2015; 73
K Winter (457_CR26) 2017; 64
References_xml – volume: 181
  start-page: 1010
  issue: 3
  year: 2000
  ident: 457_CR24
  publication-title: J Infect Dis
  doi: 10.1086/315318
  contributor:
    fullname: J Taranger
– volume: 30
  start-page: 346
  issue: 4
  year: 2018
  ident: 457_CR28
  publication-title: Ann Ig
  contributor:
    fullname: S Mazzilli
– volume: 30
  start-page: 5179
  issue: 35
  year: 2012
  ident: 457_CR25
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.06.005
  contributor:
    fullname: A Bechini
– volume: 66
  start-page: 3796
  issue: 8
  year: 1998
  ident: 457_CR43
  publication-title: Infect Immun
  doi: 10.1128/IAI.66.8.3796-3801.1998
  contributor:
    fullname: Q He
– volume: 16
  start-page: 1901
  issue: 20
  year: 1998
  ident: 457_CR20
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(98)00226-6
  contributor:
    fullname: JD Cherry
– volume: 59
  start-page: 72
  year: 2019
  ident: 457_CR41
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2019.03.006
  contributor:
    fullname: P Kapil
– volume: 27
  start-page: 1547
  issue: 12
  year: 2012
  ident: 457_CR12
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2012.27.12.1547
  contributor:
    fullname: HJ Kwon
– volume: 8
  start-page: 35
  issue: 1
  year: 2019
  ident: 457_CR14
  publication-title: Clin Exp Vaccine Res
  doi: 10.7774/cevr.2019.8.1.35
  contributor:
    fullname: C Park
– volume: 8
  start-page: 369
  issue: 4
  year: 2007
  ident: 457_CR34
  publication-title: Nat Immunol
  doi: 10.1038/ni1449
  contributor:
    fullname: SA Khader
– volume: 67
  start-page: 1426
  issue: 10
  year: 2018
  ident: 457_CR27
  publication-title: J Med Microbiol
  doi: 10.1099/jmm.0.000829
  contributor:
    fullname: H Campbell
– volume: 111
  start-page: 787
  issue: 2
  year: 2014
  ident: 457_CR33
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1314688110
  contributor:
    fullname: JM Warfel
– volume: 367
  start-page: 785
  issue: 9
  year: 2012
  ident: 457_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1209051
  contributor:
    fullname: JD Cherry
– volume: 17
  start-page: 247
  issue: 1
  year: 2017
  ident: 457_CR15
  publication-title: BMC Infect Dis
  doi: 10.1186/s12879-017-2369-x
  contributor:
    fullname: HJ Kwon
– volume: 33
  start-page: 1483
  issue: 12
  year: 2015
  ident: 457_CR40
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2015.01.063
  contributor:
    fullname: J Brummelman
– volume: 15
  start-page: 1206
  issue: 8
  year: 2009
  ident: 457_CR9
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1508.081511
  contributor:
    fullname: FR Mooi
– volume: 65
  start-page: 4904
  issue: 12
  year: 1997
  ident: 457_CR32
  publication-title: Infect Immun
  doi: 10.1128/iai.65.12.4904-4908.1997
  contributor:
    fullname: J Barbic
– volume: 161
  start-page: 1091
  issue: 6
  year: 2012
  ident: 457_CR1
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2012.05.041
  contributor:
    fullname: K Winter
– volume: 29
  start-page: 652
  issue: 5
  year: 2014
  ident: 457_CR13
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2014.29.5.652
  contributor:
    fullname: SY Lee
– volume: 61
  start-page: 399
  issue: 2
  year: 1993
  ident: 457_CR29
  publication-title: Infect Immun
  doi: 10.1128/iai.61.2.399-410.1993
  contributor:
    fullname: KH Mills
– volume: 9
  start-page: e1003264
  issue: 4
  year: 2013
  ident: 457_CR38
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1003264
  contributor:
    fullname: PJ Ross
– volume: 209
  start-page: S10
  issue: Suppl 1
  year: 2014
  ident: 457_CR45
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jit560
  contributor:
    fullname: KM Edwards
– volume: 367
  start-page: 1012
  issue: 11
  year: 2012
  ident: 457_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1200850
  contributor:
    fullname: NP Klein
– volume: 24
  start-page: 3248
  issue: 16
  year: 2006
  ident: 457_CR39
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.01.021
  contributor:
    fullname: E Reynolds
– volume: 24
  start-page: S58
  year: 2005
  ident: 457_CR4
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/01.inf.0000160914.59160.41
  contributor:
    fullname: A Wendelboe
– volume: 73
  start-page: ftv067
  issue: 8
  year: 2015
  ident: 457_CR36
  publication-title: Pathog Dis
  doi: 10.1093/femspd/ftv067
  contributor:
    fullname: J Brummelman
– volume: 181
  start-page: 1989
  issue: 6
  year: 2000
  ident: 457_CR30
  publication-title: J Infect Dis
  doi: 10.1086/315509
  contributor:
    fullname: CM Ausiello
– volume: 51
  start-page: 732
  issue: 6
  year: 2018
  ident: 457_CR17
  publication-title: J Microbiol Immunol Infect
  doi: 10.1016/j.jmii.2017.04.003
  contributor:
    fullname: DH Huh
– volume: 21
  start-page: 1924
  issue: 17–18
  year: 2003
  ident: 457_CR23
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(02)00823-X
  contributor:
    fullname: A Giammanco
– volume: 17
  start-page: 258
  issue: 2
  year: 2010
  ident: 457_CR37
  publication-title: Clin Vaccine Immunol
  doi: 10.1128/CVI.00328-09
  contributor:
    fullname: F Vermeulen
– volume: 20
  start-page: 626
  issue: 4
  year: 2014
  ident: 457_CR8
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2004.131478
  contributor:
    fullname: C Lam
– volume: 61
  start-page: 445
  issue: 6
  year: 2013
  ident: 457_CR35
  publication-title: Arch Immunol Ther Exp (Warsz)
  doi: 10.1007/s00005-013-0242-1
  contributor:
    fullname: G Fedele
– volume: 30
  start-page: 988
  issue: 7
  year: 2015
  ident: 457_CR11
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2015.30.7.988
  contributor:
    fullname: SY Lee
– volume: 67
  start-page: 4064
  issue: 8
  year: 1999
  ident: 457_CR42
  publication-title: Infect Immun
  doi: 10.1128/IAI.67.8.4064-4071.1999
  contributor:
    fullname: CM Ausiello
– volume: 93
  start-page: 1
  issue: 1
  year: 1998
  ident: 457_CR44
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.1998.00401.x
  contributor:
    fullname: M Ryan
– volume: 4
  start-page: 75
  issue: 1
  year: 2015
  ident: 457_CR16
  publication-title: Clin Exp Vaccine Res
  doi: 10.7774/cevr.2015.4.1.75
  contributor:
    fullname: SB Han
– volume: 5
  start-page: 520
  year: 2014
  ident: 457_CR21
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2014.00520
  contributor:
    fullname: G Vidarsson
– volume: 64
  start-page: 3
  issue: 1
  year: 2017
  ident: 457_CR26
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw634
  contributor:
    fullname: K Winter
– volume: 25
  start-page: 2205
  issue: 12
  year: 2019
  ident: 457_CR10
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2512.181836
  contributor:
    fullname: L Li
– volume: 13
  start-page: 151
  year: 2013
  ident: 457_CR3
  publication-title: BMC Infect Dis
  doi: 10.1186/1471-2334-13-151
  contributor:
    fullname: E Chiappini
– volume: 6
  start-page: 464
  issue: 4
  year: 1999
  ident: 457_CR19
  publication-title: Clin Diagn Lab Immunol
  doi: 10.1128/CDLI.6.4.464-470.1999
  contributor:
    fullname: JB Bruss
– volume: 16
  start-page: 1907
  issue: 20
  year: 1998
  ident: 457_CR22
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(98)00227-8
  contributor:
    fullname: J Storsaeter
– volume: 18
  start-page: E340
  issue: 9
  year: 2012
  ident: 457_CR6
  publication-title: Clin Microbiol Infect
  doi: 10.1111/j.1469-0691.2012.03925.x
  contributor:
    fullname: N Hegerle
– volume: 19
  start-page: 33
  year: 2014
  ident: 457_CR7
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES2014.19.33.20881
  contributor:
    fullname: A Zeddeman
– volume: 186
  start-page: 1843
  issue: 11
  year: 1997
  ident: 457_CR31
  publication-title: J Exp Med
  doi: 10.1084/jem.186.11.1843
  contributor:
    fullname: BP Mahon
– volume: 17
  start-page: 2651
  issue: 20–21
  year: 1999
  ident: 457_CR18
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(99)00038-9
  contributor:
    fullname: C Boursaux-Eude
SSID ssj0017828
Score 2.324168
Snippet The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of...
Abstract Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since...
Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the...
BACKGROUNDThe necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the...
Abstract Background The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 68
SubjectTerms Adhesins, Bacterial - immunology
Adolescent
Adult
Analysis
Animal models
Animals
Antibodies
Antibody response
Antigens
Bordetella pertussis
Bordetella pertussis - physiology
Cell-mediated immunity
Cells, Cultured
Diphtheria
Diphtheria-Tetanus-Pertussis Vaccine - immunology
Disease Models, Animal
DPT vaccine
Helper cells
Hemagglutinins
Humans
Immune response (humoral)
Immunity, Humoral
Immunization, Secondary
Immunogenetics
Immunogenicity
Immunogenicity, Vaccine
Innovations
Interferon gamma
Interferon-gamma - metabolism
Interleukin 17
Interleukin 5
Korea
Laboratory animals
Lymphocytes T
Methods
Mice
Mice, Inbred BALB C
Mouse study
Pertussis
Statistical analysis
Teenagers
Testing
Tetanus
Tetanus-reduced dose diphtheria-acellular pertussis vaccine
Th1 Cells - immunology
Vaccines
Virulence Factors, Bordetella - immunology
Whooping cough
Whooping Cough - immunology
γ-Interferon
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJRAXBOUVWpBBSICQVTu2k-yxRVQtUjlAK_Vm-ZXuHkhWmyxS_0Z_MTNOdrURBy4cN54oG8_Y80088w0h7xVgIGGlZGURKqZcqdnMzbAKhDtYmD6ERNd08b04u1LfrvX1TqsvzAkb6IGHiTuSdWGVkk5755FcvOKxLksHbkrHIOqhdE_oTTA1nh-A36s2JTJVcdQJLMBkmI6AGKZkYuKGElv_33vyjlOaJkzueKDTx-TRCB3p8fCXn5B7sdkn94dmkrf75MHFeEz-lNydY9VHC7YBF_pb2tbUUsDPNDbzdOJP-wigcN2xFTK3wu_QdpGGxXKe6gEts_hBHzNU6TKu-jUsnI5-vAx2-Yn-th6fQu2NXQC2pCfI3om1KHZHdtHAE3_hl_xIU7OdZ-Tq9OvllzM2Nl9gHmKMnmlf8xCECAG2IfB0euYCz10BcCe3Zai45hYEBUS1lss6Kh7zGGotouQqFlY-J3tN28SXhNZIgRMhGOYzZKfLred1qDz3qpTSqZiRzxtdmOXAsWFSbFIVZtCcAc2ZpDkjMnKC6tpKIj92ugBWY0arMf-ymoy8Q2UbZMBoMMXmxsL0mPOfP8xxUQFGRWq0jHwYheoW1O7tWLEAb4WkWRPJw4kkLFE_Hd7YlBm3iM5A3ImntDLXGXm7HcY7UWNNbNcoA3gqh6hYZeTFYILb95aqwO5xVUbKiXFOJmY60izmiUA8sRTO5Kv_MZMH5GGO6yol-RySvX61jq8Bp_XuTVqSfwCtRToY
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfGJhAvCMZXYCCDkAAhq07sfD2hFW3qkDahsUl7s_yVtg8koU2R9m_wF3PnpqUREo-NL0qTu7N_Z9_9jpB3EjBQrIVgeeYKJk2estKUWAXCDTimdS7QNZ1fZJNr-fUmvdkjk00tDKZVbubEMFG7xuIe-QhgOh5qiSQdaYO7ALYbfW5_MuwfheesfTONO-QgiSUe2B6MTy6-XW5PFGAlLDZFM0U2WsZYkskwQQFRTc7iwcIU-Pv_naV3lqlhCuXOmnT6kDzowSQ9Xmv_Ednz9SG5u24veXtI7p33B-ePye8zrANpwFrgQndLm4pqCoia-noWcgBo5wEmrpZsgVyu8Ns1S0_dvJ2FCkHNNG7xY84qbf2iW4ErLemHK6fbj_SXtvgUqqd6DmiTjpHPE6tT9I7svIYn_sC9fU9D-50n5Pr05OrLhPXtGJiFqKNjqa24c3HsHExMsPalpXE8MRkAoETnruAp1yAYQ5yruai85D7xrkpjL7j0mRZPyX7d1P45oRWS4ngIj3mJfHWJtrxyheVW5kIY6SPyaaML1a5ZN1SIVopMrTWnQHMqaE7FERmjuraSyJgdLjSLqeodUIkq01IKk1pjkaS-4L7KcwNwJ_UursqIvEVlK-TEqDHpZqrh86iz75fqOCsAtSJZWkTe90JVgyao-xoGeCuk0RpIHg0kwWntcHhjU6qfNJbqr4lH5M12GO9EjdW-WaEMIKwE4mQZkWdrE9y-t5AZ9pMrIpIPjHPwYYYj9XwWKMUDb2EpXvz_b70k9xP0mJDQc0T2u8XKvwJM1pnXvbv9AR3PNo4
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELZWi0BcECyvwIIMQuKADE7svA4I7SJWu0jlAFTam-XYTlsJkpKkiP4G_jQzTlIasQeOTSap7Jmxv4lnviHkhQQMFGohWJrYjMkijVle5FgFwgtwTGOtp2uafUrO5_LjZXx5QMZ2R8MEtleGdthPat58e_3rx_YdOPxb7_BZ8qYNsbySYbIBIpSUQTR0LZJCosXP5N9TBdgNfWkcLMgMGzONRTRXvmOyUXk-_39X7b1ta5pSubdHnd0mtwZwSU96a7hDDlx1RK737Sa3R-TGbDhIv0t-X2BdSA3WAxe6La1LqikgbOqqpc8JoJ0D2LhpWYPcrvDb1q2jdrVe-opBzTR-8sccVrp2TbcB12rpT23w9VQv9ApgJz1FYk8sU9F7QqsK_uo7fuR31PfhuUfmZx--vj9nQ18GZiD86FhsSm5tGFoLKxRsgnFeWB4VCSChSKc24zHXIBhCwKu5KJ3kLnK2jEMnuHSJFvfJYVVX7iGhJbLjOIiTeY7EdZE2vLSZ4UamQhTSBeTVqAS17uk3lA9bskT1KlOgMuVVpsKAnKKedpJIne0v1M1CDZ6oRJloKUURm8IgW33GXZmmBeCe2NmwzAPyHLWskByjwuybhYbpURdfPquTJAP4iqxpAXk5CJU16NvooZgBRoV8WhPJ44kkeK-Z3h6NSY3GryAkxQNcEcUBeba7jU-ixipXb1AGoFYEAbMMyIPe9nbjBsvHxnJZQNKJVU4mZnqnWi09t7gnMMzFo_8e32NyM0Kv8Uk-x-SwazbuCeC0rnjqne8PKhc4kw
  priority: 102
  providerName: Scholars Portal
Title Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model
URI https://www.ncbi.nlm.nih.gov/pubmed/34641798
https://www.proquest.com/docview/2590381325/abstract/
https://search.proquest.com/docview/2581822824
https://pubmed.ncbi.nlm.nih.gov/PMC8506493
https://doaj.org/article/3f6a443b5cbc426380ef77b1295ed1f9
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtx8ZextZ9eeuCNgbbGG5kS_56TEJLG0gp_YC-CVmSk8Bih8QZ9N_YX7w7xQ4xe9uLQ6wz_rg76XfS3U-EfBWAgQLFuZ_EJvVFnkR-lmdYBcJycExtjKNrmlzFF_di_BA9HJCorYVxSfs6n5-Wvxan5XzmciuXC91v88T615ORY1nLeP-QHCactyF6s3QAQ17aVsekcX8dYO2lj5kICF8SH_eG4SLGnbfSzmDkOPv_7Zn3hqZu2uTeOHT-krxoACQdbB_0FTmw5TF5ut1S8vGYPJs0i-WvyZ9LrP2owELgRP1Iq4IqCiia2nLm1v1pbQEabtb-Cvlb4b-p1paa-XLmqgKVr3BaH_NU6dKu6g24z5p-vzNq-YP-VhrvQtVUzQFh0iFyeGJFitqTnZdwxwXO51vqttx5Q-7Pz-5GF36zBYOvIdKo_UgXzJggMAY6Ixjvoiw3LMxjAD2hSkzKIqZAMIDYVjFeWMFsaE0RBZYzYWPF35Kjsirte0ILJMKxEBKzDDnqQqVZYVLNtAAd5sJ65GerC7ncMm1IF6GksdwqUYISpVOiDDwyRHXtJJEl252oVlPZ2IrkRayE4Hmkc43E9CmzRZLkAHEia4Ii88gXVLZEHowSE22mCj6PvLy9kYM4BaSKBGke-dYIFRWoXaumbgHeCqmzOpInHUlwVN1tbm1KNh3FWkL0iWu1PIw88nnXjFeixkpbbVAGUFUIsbHwyLutCe7eu7VkjyQd4-x8mG4LeJWjEW-86MN_X_mRPA_Rr1x-zwk5qlcb-wkgWp33wDEfEjimo6BHngwG49sx_A7Prq5vem7aA44Tkfac6_4FNIlBKA
link.rule.ids 230,315,733,786,790,870,891,2115,12083,12250,21416,24346,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgEY8LguUVWMAgJEDIWid2Xie0i1i1sN0DdKXeLMd22h5IQpMi7d_gFzPjpqUREsfGE6XJzNjf2DPfEPJGAgYKtRAsTWzGZJHGLC9yrALhBTimsdbTNU0uktGl_DKLZ_2GW9unVW7nRD9R29rgHvkxwHQ81BJR_LH5ybBrFJ6u9i00rpMbUgiJKX3pbBdwhbD6ZdtCmSw5bkMsw2SYlIBIJmXhYDHynP3_zsx7S9MwbXJvHTq7R-72AJKebDR-n1xz1SG5uWkpeXVIbk36w_IH5PcYaz9qsBC40F3RuqSaAoqmrlr4c3_aOYCG65atkL8Vftu6ddQum4WvCtRM47Y-5qnSxq26NbhPS99NrW7e01_a4FOonuslIEx6ihyeWJGi92SXFTzxB-7nO-pb7jwkl2efp59GrG_BwAxEGh2LTcmtDUNrYTKC9S7OC8ujIgHQE-nUZjzmGgRDiG01F6WT3EXOlnHoBJcu0eIROajqyj0htEQiHAchMc-Roy7Shpc2M9zIVIhCuoB82OpCNRumDeUjlCxRG80p0JzymlNhQE5RXTtJZMn2F-rVXPVOp0SZaClFEZvCIDF9xl2ZpgVAnNjZsMwD8hqVrZAHo8JEm7mGz6PG37-pkyQDpIoEaQF52wuVNajd6L5uAd4KqbMGkkcDSXBUMxze2pTqJ4pW_TXrgLzaDeOdqLHK1WuUAVQVQWwsA_J4Y4K79xYywR5yWUDSgXEOPsxwpFouPI245yrMxdP__62X5PZoOjlX5-OLr8_InQi9xyf0HJGDbrV2zwGTdcUL73h_ABZgNFs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF1BERUvXMrNUGBBSICQE9vr62NbiBogVQWtVPGy2puTCGJbiYNUPoMvZmZtRzG89dH2WNZ6z-ye0c6cIeR1CBzIF4y5SaxTN5RJ5GYywyoQT4JjKq2tXNPkJD4-Dz9dRBdbrb5s0r6S80HxczEo5jObW1kt1LDLExueTo6sylrGhpXOh9fJDfDZIOsC9fYAATa-tKuRSePhyscKTBfzEZDEJC52iGFhjP230t6WZJX7_1-ftzaofvLk1m40ukO-d-NoklB-DNa1HKjf_0g8Xmmgd8ntlqPSg8bkHrlmij1ys-laeblHdiftefx98meM5SUlgBBu1Je0zKmgQNSpKWY2tYDWBtjneuUuUSIWrnW5MlTPq5ktPBSuwJMDTIWllVnWa_DQFX17pkX1jv4SCr9CxVTMgcTSQ5QJxaIXsWU7L-CLCzwyMNR29XlAzkcfz46O3bbLg6sgmKndSOWe1r6vNax3sKVGmdReIGPgVYFIdOpFngBDH8Jn4bHchJ4JjM4j3zAvNLFgD8lOURbmMaE5au0YiLq9DGXwAqG8XKfKU2HCmAyNQ953E82rRsyD2yAojXmDEA4I4RYh3HfIIWJhY4lC3PZGuZzydpY4y2MRhkxGSirUvk89kyeJBBYVGe3nmUNeIZI4Sm0UmMszFfB7-PjbV34Qp0CGUYPNIW9ao7wETCnRlkbAqFCdq2e537OEtUD1H3eA5e1atOIQ4OJxMAsih7zcPMY3ccYKU67RBohbAOF36JBHDb434-7cxCFJD_m9H9N_Ani2SuUtfp9c-c0XZPf0w4h_GZ98fkpuBei_Npton-zUy7V5BoSwls-t6_8FyoFe-g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunogenicity+of+a+new+enhanced+tetanus-reduced+dose+diphtheria-acellular+pertussis+vaccine+against+Bordetella+pertussis+in+a+murine+model&rft.jtitle=BMC+immunology&rft.au=Kang%2C+Kyu+Ri&rft.au=Huh%2C+Dong+Ho&rft.au=Kim%2C+Ji+Ahn&rft.au=Kang%2C+Jin+Han&rft.date=2021-10-12&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2172&rft.eissn=1471-2172&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12865-021-00457-1&rft.externalDocID=A681630422
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2172&client=summon